The FDA asserts that Custom Ultrasonics failed to demonstrate that its AERs can effectively wash and disinfect endoscopes for the purpose of mitigating risk of patient infection. The agency recommends that all healthcare facilities using Custom Ultrasonic’s AERs begin to transition to alternative reprocessing methods for their flexible endoscopes as soon as possible.
The agency has also warned the company that if they do not comply with the orders of the recall they may seek the legal remedies of the court, including, but not limited to, civil or criminal contempt.
More articles on quality:
Giving patients access to physician notes increases satisfaction, study shows
Depression can contribute to complications and readmissions post-cancer surgery, study finds
Wasted livers: 8 points on why many donated organs unused
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
